Table 3.
Demographics on E4599 (N = 850) by treatment, divided into age/sex cohorts using age 60 as a cut-point.
| <60 yo | <60 yo | ≥60 yo | ≥60 yo | |
|---|---|---|---|---|
|
|
||||
| PC (n = 170) | PC + Bev (n = 158) | PC (n = 263) | PC + Bev (n = 259) | |
| Female | 75 (44%) | 85 (54%) | 105 (40%) | 122 (47%) |
| Male | 95 (56%) | 73 (46%) | 158 (60%) | 137 (53%) |
| PS 0 | 69 (41%) | 70 (45%) | 101 (39%) | 97 (38%) |
| PS1 | 99 (59%) | 86 (55%) | 161 (61%) | 161 (62%) |
| Stage IIIB | 26 (15%) | 18 (11%) | 29 (11%) | 32 (12%) |
| Stage IV | 144 (85%) | 140 (89%) | 234 (89%) | 227 (88%) |
| Wt loss ≥5% | 44 (26%) | 46 (29%) | 77 (29%) | 71 (27%) |
| Wt loss <5% | 126 (74%) | 112 (71%) | 186 (71%) | 188 (73%) |
PC, paclitaxel/carboplatin; Bev, Bevacizumab; 60 yo, 60 years old; PS, performance status; wt loss weight loss.